You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Autologous T Cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Hepatitis B Trial in Beijing (TCR-T)

Active, not recruiting
  • Chronic Hepatitis B
  • TCR-T
  • Beijing, China
    The Fifth Medical Center of PLA General Hospital
Jun 13, 2023

Prostate Cancer Trial in New York (engineered autologous T cells, cyclophosphamide)

Active, not recruiting
  • Prostate Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 28, 2022

Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

Active, not recruiting
  • Leukemia
  • Acute Lymphoblastic Leukemia
  • gene-modified T cells targeted
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 1, 2023

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory Trial in Memphis (drug, device, biological)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia, Refractory
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 3, 2023

Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)

Recruiting
  • Liver Cell Carcinoma
  • +7 more
  • CATCH T cells
  • +2 more
  • Houston, Texas
    Houston Methodist Hospital
Dec 19, 2022

Kidney Cancer Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (cell infusion)

Recruiting
  • Kidney Cancer
  • cell infusion
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 2, 2022

Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)

Withdrawn
  • Advanced Solid Tumor
  • TCRT-ESO-A2
  • (no location specified)
Aug 31, 2022

Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma Trial (GPC2 CAR T cells)

Not yet recruiting
  • Refractory Neuroblastoma
  • +2 more
  • GPC2 CAR T cells
  • (no location specified)
Dec 21, 2022

CNS Tumors, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant Trial in Memphis (B7-H3-CAR T cells)

Not yet recruiting
  • Central Nervous System Neoplasms
  • +6 more
  • B7-H3-CAR T cells
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Apr 18, 2023

Recurrent Glioblastoma Trial in Los Angeles (Activated T cells)

Not yet recruiting
  • Recurrent Glioblastoma
  • Activated T cells
  • Los Angeles, California
    Cedars-Sinai Medical Center
Apr 21, 2022

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
Has Results
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

Prostate Cancer Trial in Suzhou (autologous T cells & cyclophosphamide)

Recruiting
  • Prostate Cancer
  • autologous T cells & cyclophosphamide
  • Suzhou, China
    The First Affiliated Hospital of Soochow University
Feb 8, 2023

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Solid Tumors Trial in New York (procedure, drug, device, genetic)

Active, not recruiting
  • Solid Tumors
  • Production of Genetically-modified T cells
  • +4 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Sep 1, 2022

Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant Trial (SynKIR-110, Autologous T cells Transduced with

Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
  • (no location specified)
Oct 5, 2022

Ovarian Cancer Trial in Tampa (Follicle Stimulating Hormone Receptor T Cells)

Recruiting
  • Ovarian Cancer
  • Follicle Stimulating Hormone Receptor T Cells
  • Tampa, Florida
    Moffitt Cancer Center
Mar 30, 2022

Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer Trial in Houston (Neoantigen specific TCR-T cell drug product,

Recruiting
  • Gynecologic Cancer
  • +11 more
  • Neoantigen specific TCR-T cell drug product
  • Aldesleukin (IL-2)
  • Houston, Texas
    MD Anderson Cancer Center
Jul 27, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

Subjects Treated With Autologous T Cells Using Sleeping Beauty

Not yet recruiting
  • Gynecologic Cancer
  • +9 more
  • Neoantigen specific TCR-T cell drug product
  • Houston, Texas
    MD Anderson Cancer Center
Jul 27, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

Gastric Cancer, Pancreatic Cancer, Advanced Ovarian Carcinoma Trial (Claudin 18.2 CAR-T)

Not yet recruiting
  • Gastric Cancer
  • +3 more
  • Claudin 18.2 CAR-T
  • (no location specified)
Jul 21, 2022

Diffuse Midline Glioma, H3 K27M-Mutant Trial in San Francisco (Cyclophosphamide, Fludarabine, Autologous Anti-H3.3K27M

Not yet recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • San Francisco, California
    University of California, San Francisco
Aug 15, 2022

Malignant Pleural Disease, Mesothelioma, Metastases Trial in United States (iCasp9M28z T cell infusions, cyclophosphamide,

Active, not recruiting
  • Malignant Pleural Disease
  • +4 more
  • iCasp9M28z T cell infusions
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
Nov 14, 2022